DUPIXENT improved nasal congestion and obstruction as early as Week 4 as measured by NC score in SINUS-52: -0.52 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) vs -0.16 with placebo + INCS (n=153) (LSM difference vs placebo: -0.37 [95% CI: -0.46, -0.27]).^1,6

At Week 24 in the same study, patients experienced a 51% improvement in their NC score with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 16% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference vs placebo: -0.87 [95% CI: -1.03, -0.71]).¹

Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See the full data on nasal congestion and obstruction